الفهرس Only 14 pages are availabe for public view
 |  | from | 178 |  |  |
| | | from | 178 | | |
Abstract
Hemangioma is the most common infancy tumor. Hemangioma-derived endothelial cells (ECs) are clonal. Endothelial progenitor cells (EPCs), are found predominantly in proliferating but not involuting or involuted hemangioma, a finding suggests that EPCs contribute to the early growth of hemangioma. CD133 is a novel human stem/progenitor cell marker that is expressed only on EPCs. The aim of the present work is to evaluate CD133 gene expression in hemangioma tissue by real time quantitative reverse transcription PCR (RT-PCR) and to correlate the predictor efficacy of CD133 for hemangioma complications and the need and response for therapeutic intervention. The entire control group was negative for CD133 expression, while among hemangioma group, 47 patients (70%) were positive for CD133 expression with an expression range of 0.00 to 2.11, a median of 0.390. Patients with ungrowing hemangiomas had a significantly lower CD133 median expression values compared to patients with growing hemangiomas (P<0.001). The incidence of complications as well as the incidence of peripheral limbs hemangiomas were significantly higher in CD133 positive group compared to CD133 negative group (P=0.012). The incidence of moderate to poor response to treatment was significantly higher in the CD133 positive group compared to the CD133 negative group (P=0.042). Patients with poor to moderate prognosis had a significantly higher CD133 median expression values compared to patients with good to excellent prognosis (P=0.014). In conclusion, CD133 expression in infantile hemangioma was significantly higher compared to the control group, cases with positive expression experienced more complications and had poorer outcome